Maravai Lifesciences (MRVI) Stock
Biopharma and life science reagent and manufacturing supplier. Here's the price, business snapshot, and what's worth knowing about Maravai Lifesciences in August 2026.
Maravai LifeSciences (MRVI) supplies reagents, specialised biomaterials and contract development and manufacturing services to the biopharma and life-science research sectors. The company’s product mix includes nucleic-acid reagents, mRNA and gene-modification enabling technologies, plus manufacturing support that saw heightened demand during the mRNA vaccine rollout. For investors, key attractions are exposure to structural growth in gene therapy, mRNA therapeutics and biomanufacturing outsourcing. Important risks include cyclical demand tied to biotech R&D and vaccine campaigns, customer concentration, and competitive pressures from larger suppliers. Financial metrics and pipeline visibility can swing materially quarter to quarter, so volatility is possible. This summary is for general, educational purposes and not personal advice; suitability depends on your financial situation and risk tolerance. Always do your own research and consider consulting a regulated adviser before making investment decisions.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Maravai LifeSciences stock, expecting it to rise to $9.
Financial Health
Maravai is achieving solid revenue and cash flow, but its profit margins are modest.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
mRNA & Gene Tools
Maravai supplies building blocks for mRNA and gene‑editing work, a sector with durable scientific interest — though demand can ebb with funding cycles.
Contract Manufacturing Growth
Its CDMO-like services tap growth as firms outsource production, but revenue can be lumpy and tied to a few large customers.
Steady R&D Momentum
Ongoing investment in R&D and product breadth can sustain long-term relevance; investors should weigh this against competition and operational risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.